VIRTUAL – Education Session “Discover a New Investigational Approach to VWD Treatment”

RSVP HERE!

Join Us for a Virtual Education Session during VWD Awareness Week

March is Bleeding Disorders Awareness Month, and in recognition of Von Willebrand Disease (VWD) Awareness Week (March 1–7), we are pleased to host the virtual educational session “Discover a New Investigational Approach to VWD Treatment” featuring Star Therapeutics.

Star Therapeutics is currently investigating VGA039, a potential once-monthly subcutaneous prophylactic treatment for VWD.

If you or someone in your family has any type of VWD or you are curious about new therapies in the bleeding disorders community, we invite you to join us for this informative and engaging session. Dr. Laura Guido, Head of Medical Affairs at Star Therapeutics, will discuss:

• How VGA039 works
• The clinical development pathway for this investigational therapy
• Early clinical trial results
• Information about the VIVID Clinical Trials, including how to explore eligibility and participation

Featured Speaker

Laura Guido, PharmD, MBA, BCPS
Executive Director, Medical Affairs, Star Therapeutics

Dr. Guido is a clinical pharmacist who leads Medical Affairs for VGA039 at Star Therapeutics. Prior to joining Star, she supported clinical development for hemophilia A gene therapy trials at BioMarin and spent several years working in anticoagulation at Boehringer Ingelheim. Before transitioning to industry, Dr. Guido practiced as a clinical pharmacist.